Swedish biotech venture LIDDS AB has received approval from the Danish Medicines Agency (DKMA) to conduct a Phase I trial–NZ-DTX-001. This is in addition to a study already approved in Sweden at the Karolinska University Hospital. The aim of the trial is to...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
